X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1125) 1125
Publication (120) 120
Book Review (35) 35
Newspaper Article (10) 10
Book Chapter (5) 5
Conference Proceeding (3) 3
Dissertation (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (731) 731
multiple sclerosis (710) 710
humans (693) 693
oral fingolimod (643) 643
clinical neurology (430) 430
fingolimod (393) 393
female (327) 327
male (305) 305
immunosuppressive agents - therapeutic use (301) 301
sphingosine - analogs & derivatives (291) 291
multiple sclerosis - drug therapy (274) 274
fingolimod hydrochloride (269) 269
fty720 (260) 260
multiple sclerosis, relapsing-remitting - drug therapy (257) 257
placebo-controlled trial (257) 257
double-blind (252) 252
adult (248) 248
animals (245) 245
pharmacology & pharmacy (245) 245
neurosciences (233) 233
relapsing multiple-sclerosis (217) 217
administration, oral (215) 215
middle aged (180) 180
neurology (178) 178
treatment outcome (167) 167
interferon (166) 166
immunosuppressive agents - adverse effects (156) 156
propylene glycols - therapeutic use (155) 155
natalizumab (153) 153
immunosuppressive agents - administration & dosage (151) 151
sphingosine - therapeutic use (151) 151
drug therapy (143) 143
experimental autoimmune encephalomyelitis (132) 132
fingolimod hydrochloride - therapeutic use (127) 127
safety (126) 126
immunosuppressive agents - pharmacology (117) 117
glatiramer acetate (113) 113
sphingosine 1-phosphate (113) 113
immunology (112) 112
efficacy (110) 110
placebo-controlled phase-3 (108) 108
mice (106) 106
research (106) 106
propylene glycols - administration & dosage (105) 105
magnetic resonance imaging (103) 103
care and treatment (102) 102
trial (102) 102
intramuscular interferon (101) 101
clinical trials (98) 98
sphingosine-1-phosphate (96) 96
sphingosine - administration & dosage (95) 95
medicine, general & internal (94) 94
progressive multifocal leukoencephalopathy (93) 93
central-nervous-system (92) 92
disease progression (92) 92
patients (91) 91
therapy (91) 91
young adult (91) 91
dimethyl fumarate (90) 90
analysis (88) 88
receptors, lysosphingolipid - metabolism (85) 85
propylene glycols - pharmacology (82) 82
propylene glycols - adverse effects (81) 81
lymphocytes (80) 80
sphingosine (80) 80
sphingosine - adverse effects (80) 80
dosage and administration (78) 78
sphingosine - pharmacology (78) 78
multicenter (76) 76
oral fingolimod fty720 (76) 76
teriflunomide (74) 74
lymphocyte egress (73) 73
review (73) 73
immunologic factors - therapeutic use (71) 71
interferon beta-1a (71) 71
medicine & public health (71) 71
fingolimod hydrochloride - adverse effects (69) 69
multiple-sclerosis (68) 68
rats (68) 68
abridged index medicus (67) 67
alemtuzumab (66) 66
phosphates (66) 66
article (64) 64
disability (62) 62
psychiatry (62) 62
t-cells (61) 61
multiple sclerosis - immunology (60) 60
disease-modifying therapies (59) 59
medicine (59) 59
inflammation (58) 58
disease (57) 57
interferon-beta (57) 57
oral teriflunomide (56) 56
dose-response relationship, drug (55) 55
double-blind method (55) 55
disability evaluation (54) 54
fingolimod hydrochloride - administration & dosage (52) 52
oral bg-12 (52) 52
studies (52) 52
adolescent (51) 51
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1060) 1060
German (34) 34
Spanish (22) 22
Hungarian (8) 8
French (5) 5
Russian (4) 4
Japanese (3) 3
Czech (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Fundamental & Clinical Pharmacology, ISSN 0767-3981, 08/2017, Volume 31, Issue 4, pp. 392 - 402
Cardiac arrhythmias and ECG abnormalities including bradycardia, prolongation of the QT interval, and atrioventricular ( AV ) conduction blocks have been... 
ECG | calcium currents | cardiac arrhythmias | action potentials | fingolimod | CARDIAC-FUNCTION | ORAL FINGOLIMOD | PIG ATRIAL MYOCYTES | HEALTHY-SUBJECTS | POTASSIUM CHANNELS | VENTRICULAR MYOCYTES | LYMPHOCYTE EGRESS | SPHINGOSINE 1-PHOSPHATE | PHARMACOLOGY & PHARMACY | RENAL-TRANSPLANT PATIENTS | PLACEBO-CONTROLLED TRIAL | Fingolimod Hydrochloride - pharmacology | Heart - physiology | Immunosuppressive Agents - therapeutic use | Calcium Channel Blockers - therapeutic use | Male | Atrioventricular Block - chemically induced | Heart Rate - drug effects | Multiple Sclerosis - physiopathology | Heart Conduction System - physiology | Heart Rate - physiology | Immunosuppressive Agents - pharmacology | Fingolimod Hydrochloride - therapeutic use | Fingolimod Hydrochloride - toxicity | Atrioventricular Block - physiopathology | Guinea Pigs | Bradycardia - physiopathology | Calcium Channels, L-Type - physiology | Heart Conduction System - drug effects | Calcium Channel Blockers - pharmacology | Immunosuppressive Agents - toxicity | Calcium Channel Blockers - toxicity | Bradycardia - chemically induced | Animals | Heart - drug effects | Multiple Sclerosis - drug therapy | Phosphates | Heart | Bradycardia | Calcium channels | Multiple sclerosis | Electrocardiogram | Electrocardiography | EKG | Pigs | Cardiac arrhythmia | Conduction | Surgical implants | Calcium | Abnormalities | Calcium channels (voltage-gated) | Electrophysiology | Action potential | Exposure | Experiments | Nerve conduction | Perfusion | Phosphate | Calcium channels (L-type) | Heart diseases | In vitro methods and tests | Prolongation
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 1/2011, Volume 108, Issue 2, pp. 751 - 756
Journal Article